Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Microbicides news

Show

From To
Are antimicrobial condoms the new frontier against STIs? Not quite…

Australian biotech company Starpharma has announced the imminent launch of a condom coated with an antimicrobial chemical known as VivaGel. While it might be marketed as a great leap forward for preventing sexually transmitted infections (STIs), it’s unlikely to offer any more protection than your average condom.

Published
14 October 2014
From
The Conversation
Advocates Applaud Launch of MTN-017, World’s First Phase II Rectal Microbicide Study

IRMA applauds the launch of the world’s first-ever Phase II rectal microbicide trial. The Microbicide Trial Network’s study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally. Volunteers consisting of gay men, other men who have sex with men, and transgender women will participate in the study at sites in the United States and in Thailand, South Africa, and Peru.

Published
02 October 2014
From
IRMA
Give Some LOVE to IRMA for Give OUT Day

Give OUT Day shines a spotlight on organizations that empower LGBTQ communities across the country, and the AIDS Foundation of Chicago (AFC) is among these charities.We’re using this campaign to highlight the next generation of HIV prevention: rectal microbicides. Though they’re still in development, these agents can be added to things like lubricants that will prevent the transmission of HIV, revolutionizing the way we protect ourselves and others.

Published
25 September 2014
From
IRMA
Stigma, ambivalence and other priorities – explaining poor adherence to PrEP and vaginal microbicides

HIV stigma, the danger of being mistakenly labelled as having HIV, ambivalence about the research process, confusion about the use of antiretrovirals to prevent infection, as well

Published
19 September 2014
By
Roger Pebody
HIV-fighting intravaginal ring research nets $20M from NIH

The U.S. National Institutes of Health devoted $20 million to a group of institutions including Miriam Hospital in Rhode Island to develop an HIV drug-delivering intravaginal ring. The design of a successful ring is a priority in HIV research, and the sustained release of drugs the ring offers could eventually play a crucial role in HIV prevention in the developing world.

Published
15 September 2014
From
Fierce Drug Delivery
Learning about additional HIV prevention methods doesn’t undermine gay men’s intentions to use condoms

Health promotion interventions can combine information about condoms and alternative biomedical prevention methods without undermining attitudes and intentions to use condoms, according to an experimental study published in

Published
15 September 2014
By
Roger Pebody
Semi-soft vaginal drug-delivery suppository could limit spread of HIV, AIDS

A unique method for delivering compounds that could positively impact the global battle against HIV and AIDS may be possible, thanks to researchers in Penn State's College of Agricultural Sciences. A semi-soft vaginal suppository made from the seaweed-derived food ingredient carrageenan and loaded with the antiviral drug Tenofovir provides a woman-initiated, drug-delivery vehicle that can protect against the spread of sexually transmitted infections during unprotected heterosexual intercourse, the researchers said.

Published
02 September 2014
From
Medical News Today
Weaving HIV protection: UW researchers use fabric to protect women against infection

Scientists use a method of weaving the drug into silk-like fibers that dissolve quickly when inserted into the vagina before sex, delivering a higher dose than is possible with other topical methods currently being tested.

Published
05 August 2014
From
Business Journal
ASPIRE Phase III trial of a vaginal ring for HIV prevention completes enrollment of 2,629 women

MTN’s trial testing dapivirine ring on track to finish next year; IPM’s sister Phase III trial ongoing.

Published
30 June 2014
From
Microbicide Trials Network
Rectal tenofovir gel yields much higher rectal and vaginal levels than oral tenofovir

Tenofovir 1% gel applied rectally yielded rectal tissue concentrations orders of magnitude greater than those achieved with oral tenofovir, according to results of an 18-person study by US researchers. Systemic tenofovir exposure was lower with 1% gel than with oral tenofovir, but vaginal exposure was greater with the rectal gel.

Published
02 June 2014
From
NATAP
← First12345...18Next →

Filter by country